CS
PRTK

Credit Suisse’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Credit Suisse’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26
Closed – – 4431
2022
Q2 		$0 Buy
+26
New +$57 ﹤0.01% 4495
2021
Q1 		– Sell
-15,226
Closed -$96K – 4644
2020
Q4 		$96K Buy
+15,226
New +$89.6K ﹤0.01% 4186
2019
Q2 		– Sell
-17,820
Closed -$95K – 4272
2019
Q1 		$95K Buy
17,820
+4,979
+39% +$32.1K ﹤0.01% 3851
2018
Q4 		$66K Buy
12,841
+2,008
+19% +$15.2K ﹤0.01% 3788
2018
Q3 		$106K Sell
10,833
-17,978
-62% -$181K ﹤0.01% 3718
2018
Q2 		$294K Sell
28,811
-1,102
-4% -$12.5K ﹤0.01% 3638
2018
Q1 		$389K Buy
29,913
+840
+3% +$12.5K ﹤0.01% 3475
2017
Q4 		$520K Sell
29,073
-9,019
-24% -$188K ﹤0.01% 3421
2017
Q3 		$956K Buy
38,092
+23,387
+159% +$544K ﹤0.01% 3136
2017
Q2 		$354K Sell
14,705
-3,405
-19% -$75.3K ﹤0.01% 3371
2017
Q1 		$349K Buy
18,110
+4,853
+37% +$76.5K ﹤0.01% 3469
2016
Q4 		$204K Sell
13,257
-3,027
-19% -$39.3K ﹤0.01% 3808
2016
Q3 		$212K Buy
16,284
+5,649
+53% +$74.9K ﹤0.01% 3787
2016
Q2 		$148K Buy
+10,635
New +$157K ﹤0.01% 3973
2015
Q2 		– Sell
-28,825
Closed -$901K – 4673
2015
Q1 		$901K Buy
28,825
+14,094
+96% +$405K ﹤0.01% 3063
2014
Q4 		$568K Buy
+14,731
New +$352K ﹤0.01% 3607

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

Credit Suisse's PRTK Position: Q3 2022 in Review

Credit Suisse sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2022, closing a stake of 26 shares.

Credit Suisse first reported a position in PRTK in Q4 2014 and held it in 16 quarters. The position peaked at $956K in Q3 2017. 72 funds tracked by Wall St. Rank hold PRTK as of Q3 2022.

  • Credit Suisse reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 26 Paratek Pharmaceuticals, Inc. shares in Q3 2022.
  • Credit Suisse first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and held it in 16 quarters.
  • Credit Suisse's Paratek Pharmaceuticals, Inc. position peaked at $956K in Q3 2017.
  • 72 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.